An interventional study of MDT-Based Umbrella Decision-Making Model in Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by West China Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.
Among the 850 studies in Lung Neoplasms with a site in China, this one is the 19th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 214 with no phase, reaches primary completion later than 418 of the 422 other live ones, and was the 765th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:
Zhongnan Hospital · Sites in China
Ages 18+ · Healthy volunteers
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
West China Hospital · Sites in China
Ages 18–80
Xiamen University · Sites in China
Ages 18–80
AstraZeneca · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 226 · Phase 3 77 · Phase 4 9
First in 1992; this study’s year is marked. 92 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 90 across the 590 interventional studies, 307 across the 259 observational. Of the 208 that completed or were terminated, 36 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 850 have an industry lead sponsor. The 10 most frequent:
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
West China Hospital has 8 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
118 of the studies in Lung Neoplasms with a site in China that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607796Phase 3Zhou ChengzhiEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT07162883Phase 3Qilu Pharmaceutical Co., Ltd.Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | 2026-12-31 |
| NCT04841811Phase 3Guangdong Association of Clinical TrialsMDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH) | 2026-12-31 |
| NCT06598527Phase 3Yang HongStereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study | 2027-01-30 |
Add all 118 to your calendar (.ics) → With an account.
Among the 850 studies in Lung Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, prospective, single-arm interventional study with historical control, designed to evaluate the clinical value of a multidisciplinary team (MDT)-based decision-making umbrella decision model in elderly patients with lung cancer. A total of 2,000 patients aged 60-90 years with newly diagnosed non-small cell or small cell lung cancer will be enrolled. Each patient will undergo comprehensive geriatric assessment and receive an individualized treatment plan formulated by an MDT comprising thoracic surgeons, geriatricians, oncologists, pulmonologists, rehabilitation therapists, and radiologists. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. The primary outcome is 3-year progression-free survival (PFS). Secondary outcomes include overall survival, objective response rate, quality of life (EORTC QLQ-LC43), incidence of adverse events (CTCAE v5.0), and healthcare economics. Historical controls (2014-2024) will be extracted from hospital records and matched using propensity score matching. The study aims to establish a standardized MDT pathway to improve treatment outcomes and reduce risks in the geriatric lung cancer population.
Background:
China faces a dual epidemiological trend of aging and increasing non-smoking-related lung cancer. Elderly patients (≥60 years) now constitute the majority of lung cancer cases but are often underrepresented in clinical trials. They present unique challenges including physiological decline, multiple comorbidities, and high heterogeneity, which cannot be adequately addressed by single-discipline decision-making. Multidisciplinary team (MDT) models have shown promise in improving outcomes, yet standardized geriatric-specific pathways remain lacking.
Objective:
To establish and validate an MDT-based umbrella decision-making model for elderly lung cancer patients, integrating comprehensive geriatric assessment (CGA) and individualized treatment planning across multiple therapeutic modalities.
Study Design:
This is a prospective, single-arm interventional study conducted at West China Hospital, Sichuan University. A historical control cohort (2014-2024) will be extracted from the hospital information system. The primary historical comparison will use patients treated during the most recent pre-implementation period (2021-2024) to reduce differences in staging, imaging, molecular testing, and access to targeted and immunotherapies. Patients treated during 2014-2020 will be included only in era-stratified sensitivity analyses.
Participants:
A total of 2,000 elderly patients (age 60-90 years) with histologically or cytologically confirmed lung cancer (stage I-IV) will be enrolled. Inclusion criteria also include ECOG PS 0-2, life expectancy ≥3 months, and written informed consent. Exclusion criteria include other active malignancies, severe cognitive impairment (MMSE \<20), contraindications to examinations, severe organ failure, and concurrent participation in other interventional trials.
Intervention:
All enrolled patients undergo MDT discussion involving thoracic surgery, geriatrics, respiratory medicine, oncology, rehabilitation, and radiology. The MDT formulates a personalized treatment plan based on tumor characteristics and CGA results (including nutritional, functional, and psychological status). Treatments may include:
Standardized perioperative management and long-term follow-up (up to 5 years) are implemented. Follow-up assessments include imaging (CT, MRI, PET/CT as indicated), pulmonary function tests, quality of life questionnaires (EORTC QLQ-LC43), and adverse event monitoring.
Outcomes:
Statistical Analysis:
Analyses will be performed on full analysis set (FAS), per-protocol set (PPS), and safety set (SS). Survival curves will be estimated using Kaplan-Meier method and compared by log-rank test. Multivariable Cox regression will identify independent prognostic factors. Propensity score matching will be used to compare MDT group with historical controls. Missing data will be handled by multiple imputation.
Ethics and Dissemination:
The prospective study protocol has been approved by the Ethics Committee of West China Hospital, Sichuan University (Approval No. 1773, 2025). The use of retrospective medical record data from 2014 to 2024 has been separately approved by the same Ethics Committee (Approval No. 2287, 2025). Written informed consent will be obtained from all prospectively enrolled participants, while the consent requirements for the retrospective cohort will be handled in accordance with the corresponding ethics approval. The study will be conducted in accordance with the Declaration of Helsinki and applicable Chinese regulations. Results will be disseminated through peer-reviewed publications and conference presentations.
Safety Monitoring: An independent data monitoring committee is not planned because the study evaluates a CGA-informed MDT care pathway and does not mandate the use of an investigational drug or device. All specific anticancer treatments will be delivered according to routine clinical practice and applicable treatment guidelines.Adverse events will be identified and managed by the treating clinical team. Serious adverse events will be reported to the principal investigator within 24 hours after awareness and reported to the Ethics Committee in accordance with institutional requirements.A study safety monitoring group comprising investigators from relevant clinical disciplines will review serious adverse events, grade 3 or higher treatment-related adverse events, unexpected study-related risks, and major protocol deviations at prespecified intervals. The group may recommend protocol modification, additional participant protection measures, or temporary suspension of study-specific procedures when necessary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive individualized treatment plans formulated by a multidisciplinary team (MDT) based on comprehensive geriatric assessment and tumor characteristics. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. All patients undergo standardized follow-up according to protocol.
Other: MDT-Based Umbrella Decision-Making Model
A structured multidisciplinary team (MDT) umbrella decision-making model for geriatric lung cancer patients. The MDT, comprising specialists from thoracic surgery, geriatrics, respiratory medicine, oncology, rehabilitation, and radiology, conducts comprehensive reviews of each patient's clinical data, including comprehensive geriatric assessment, tumor pathology, results of clinically indicated tumor somatic molecular testing when available, and functional status. Based on this evaluation, the team formulates and oversees the implementation of individualized treatment plans across multiple therapeutic modalities (surgery, ablation, SBRT, targeted therapy, immunotherapy, etc.) and standardized follow-up protocols, tailored to distinct patient subgroups within the umbrella trial framework.
3-Year Progression-Free Survival (PFS)
Progression-free survival is defined as the time from the start of initial treatment to the first occurrence of disease progression (assessed by RECIST version 1.1 criteria) or death from any cause, whichever occurs first. The 3-year PFS rate will be reported.
Time frame: Up to 3 years
Overall Survival (OS)
Overall survival is defined as the time from the start of initial treatment to death from any cause. OS rates at 1, 3, and 5 years will be estimated.
Time frame: Up to 5 years
Disease-Free Survival (DFS)
Disease-free survival is defined as the time from curative-intent treatment (e.g., surgery, SBRT, ablation) to first recurrence or death from any cause, whichever occurs first. DFS rates at 1, 3, and 5 years will be reported for patients receiving curative-intent therapy.
Time frame: Up to 5 years
Objective Response Rate (ORR)
ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR).
Time frame: Up to 5 years
Change in Quality of Life (EORTC QLQ-LC43)
Quality of life is assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 43 (QLQ-LC43). Mean change from baseline in global health status and symptom scales will be evaluated at multiple time points.
Time frame: Up to 5 years
Healthcare Economic Outcomes
Total medical costs (including direct costs of treatment, hospitalization, and follow-up) and hospital readmission rates will be compared between the MDT group and historical control group.
Time frame: Up to 5 years
Disease Control Rate (DCR)
DCR is defined as the proportion of patients with CR, PR, or stable disease (SD) according to RECIST v1.1 criteria.
Time frame: Up to 5 years
Plan to share: No — Individual participant data will not be made publicly available because the dataset contains sensitive clinical, imaging, and potentially genomic information and is subject to institutional and applicable national data-protection requirements. The study protocol, statistical analysis plan, and de-identified aggregate results may be made available upon reasonable request and approval by the responsible institution.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2033, 84 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 84 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.